Search results for "lung neoplasm"

showing 10 items of 434 documents

Quantitative analysis of airway obstruction in lymphangioleiomyomatosis

2020

Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease with progressive pulmonary function loss caused by progressively proliferating LAM cells. The degree of airway obstruction has not been well investigated within the pathogenesis of LAM. Using a combination of ex vivo computed tomography (CT), microCT and histology, the site and nature of airway obstruction in LAM explant lungs was compared with matched control lungs (n=5 each). The total number of airways per generation, total airway counts, terminal bronchioles number and surface density were compared in LAM versus control. Ex vivo CT analysis demonstrated a reduced number of airways from generation 7 on (p<0.0001) in LAM compar…

Pulmonary and Respiratory MedicineLipopolysaccharidesPathologymedicine.medical_specialtyLung NeoplasmsPulmonary function testingPathogenesisOrphan Lung Diseases03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineMedicine and Health SciencesFLOW OBSTRUCTIONMedicineHumans030212 general & internal medicineLymphangioleiomyomatosisBronchiolesLungbusiness.industryHistologyOriginal ArticlesX-Ray MicrotomographyAirway obstructionrespiratory systemmedicine.disease133. Good healthrespiratory tract diseasesAirway Obstruction030228 respiratory systemPULMONARY LYMPHANGIOLEIOMYOMATOSISLymphangioleiomyomatosisHuman medicineAirwaybusinessQuantitative analysis (chemistry)Ex vivoCTThe European Respiratory Journal
researchProduct

CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC

2019

Abstract Although EGFR mutant–selective tyrosine kinase inhibitors (TKI) are clinically effective, acquired resistance can occur by reactivating ERK. We show using in vitro models of acquired EGFR TKI resistance with a mesenchymal phenotype that CXCR7, an atypical G protein-coupled receptor, activates the MAPK–ERK pathway via β-arrestin. Depletion of CXCR7 inhibited the MAPK pathway, significantly attenuated EGFR TKI resistance, and resulted in mesenchymal-to-epithelial transition. CXCR7 overexpression was essential in reactivation of ERK1/2 for the generation of EGFR TKI–resistant persister cells. Many patients with non–small cell lung cancer (NSCLC) harboring an EGFR kinase domain mutatio…

0301 basic medicineMAPK/ERK pathwayCancer ResearchLung NeoplasmsDrug ResistanceDrug resistanceTransgenicMiceChemokine receptor0302 clinical medicineNeoplasmsCarcinoma Non-Small-Cell LungReceptorsMedicineNon-Small-Cell LungCXCRReceptorLungbeta-ArrestinsCancerEGFR inhibitorsTumorKinaseLung CancerErbB ReceptorsOncology5.1 Pharmaceuticals030220 oncology & carcinogenesisDevelopment of treatments and therapeutic interventionsTyrosine kinaseEpithelial-Mesenchymal TransitionMAP Kinase Signaling SystemOncology and CarcinogenesisMice TransgenicArticleCell LineExperimental03 medical and health sciencesClinical ResearchCell Line TumorAnimalsHumansOncology & CarcinogenesisProtein Kinase InhibitorsReceptors CXCRbusiness.industryCarcinomaNeoplasms Experimentalrespiratory tract diseases030104 developmental biologyProtein kinase domainDrug Resistance NeoplasmMutationCancer researchNeoplasmbusinessCancer Research
researchProduct

Dosimetric effect of respiratory motion on planned dose in whole-breast volumetric modulated arc therapy using moderate and ultra-hypofractionation.

2021

Abstract Background and purpose The interplay effect of respiratory motion on the planned dose in free-breathing right-sided whole-breast irradiation (WBI) were studied by simulating hypofractionated VMAT treatment courses. Materials and methods Ten patients with phase-triggered 4D-CT images were included in the study. VMAT plans targeting the right breast were created retrospectively with moderately hypofractionated (40.05 Gy in 15 fractions of 2.67 Gy) and ultra-hypofractionated (26 Gy 5 fractions of 5.2 Gy) schemes. 3D-CRT plans were generated as a reference. All plans were divided into respiratory phase-specific plans and calculated in the corresponding phase images. Fraction-specific d…

Lung Neoplasmsrespiratory motionrintasyöpäultrahypofractionationwhole-breast irradiationRadiotherapy Dosagevolumetric modulated arc therapysädehoitobreast cancersäteilyannoksetOncologyhengitysHumansRadiology Nuclear Medicine and imagingRadiation Dose HypofractionationRadiotherapy Intensity-ModulatedradiologiaRadiometryRetrospective StudiesRadiation oncology (London, England)
researchProduct

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-dr…

2017

Background Studying the intracellular distribution of pharmacological agents, including anticancer compounds, is of central importance in biomedical research. It constitutes a prerequisite for a better understanding of the molecular mechanisms underlying drug action and resistance development. Hyperactivated fibroblast growth factor receptors (FGFRs) constitute a promising therapy target in several types of malignancies including lung cancer. The clinically approved small-molecule FGFR inhibitor nintedanib exerts strong cytotoxicity in FGFR-driven lung cancer cells. However, subcellular pharmacokinetics of this compound and its impact on therapeutic efficacy remain obscure. Methods 3-dimens…

IndolesLung NeoplasmsNintedanibResistancelcsh:RC254-282FluorescenceMiceCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansPhosphorylationLungCell ProliferationAntineoplastic Combined Chemotherapy ProtocolAnimalResearchDrug Synergismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensLysosomeReceptors Fibroblast Growth FactorXenograft Model Antitumor AssaysLung NeoplasmFGFR1IndoleSettore CHIM/03 - Chimica Generale E InorganicaMacrolidesMacrolideLysosomesHumanSignal Transduction
researchProduct

RGD motifs on the surface of baculovirus enhance transduction of human lung carcinoma cells.

2006

Baculovirus vectors have been shown to enter a variety of mammalian cell lines and gene transfer with wild-type baculovirus (WT) has been demonstrated both in vitro and in vivo. Different protein motifs have been displayed on the viral surface to serve as ligands for cell-specific receptor molecules. We have generated recombinant baculovirus vectors displaying an RGD-motif, recognized by alphaV integrin, on the viral surface. The RGD motifs within the C-terminus of coxsackie virus A9 and human parechovirus 1 VP1 proteins were fused to the N-terminus of the major envelope glycoprotein, gp64, of Autographa californica multiple nucleopolyhedrovirus. The recombinant RGD-presenting viruses bound…

Lung NeoplasmsvirusesRecombinant Fusion ProteinsIntegrinBlotting WesternGenetic VectorsBioengineeringPlasma protein bindingTransfectionApplied Microbiology and Biotechnologylaw.inventionTransduction (genetics)lawCell Line TumorAnimalsHumansCells CulturedRGD motifMicroscopy ConfocalbiologyModels GeneticGeneral MedicineTransfectionMolecular biologyIntegrin alphaVbiology.proteinRecombinant DNALight emissionElectrophoresis Polyacrylamide GelBaculoviridaeOligopeptidesBiotechnologyProtein BindingJournal of biotechnology
researchProduct

Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma.

2021

Kinase fusions are considered oncogenic drivers in numerous types of cancer. In lung adenocarcinoma 5-10% of patients harbor kinase fusions. The most frequently detected kinase fusion involves the Anaplastic Lymphoma Kinase (ALK) and Echinoderm Microtubule-associated protein-Like 4 (EML4). In addition, oncogenic kinase fusions involving the tyrosine kinases RET and ROS1 are found in smaller subsets of patients. In this study, we employed quantitative mass spectrometry-based phosphoproteomics to define the cellular tyrosine phosphorylation patterns induced by different oncogenic kinase fusions identified in patients with lung adenocarcinoma. We show that exogenous expression of the kinase fu…

ProteomicsLung NeoplasmsOncogene Proteins FusionAdenocarcinoma of LungBiologyBiochemistry03 medical and health scienceschemistry.chemical_compoundProto-Oncogene ProteinsmedicineROS1Anaplastic lymphoma kinaseHumansddc:610PhosphorylationLung cancerMolecular Biology030304 developmental biology0303 health sciencesKinase030302 biochemistry & molecular biologyProto-Oncogene Proteins c-retPhosphoproteomicsTyrosine phosphorylationProtein-Tyrosine Kinasesmedicine.diseasechemistryCancer researchPhosphorylationTyrosineTyrosine kinaseProteomicsREFERENCES
researchProduct

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management

2004

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management

Cancer ResearchPathologymedicine.medical_specialtyIntroductionLung Neoplasmsbusiness.industryInterstitial lung diseaserespiratory systemmedicine.diseaserespiratory tract diseasesText miningOncologyCarcinoma Non-Small-Cell LungmedicineHumansIn patientNon small cellbusinessLung cancerLung Diseases InterstitialBritish Journal of Cancer
researchProduct

Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases : a population-based study

2020

Background This population‐based study aimed to examine the incidence, patterns and results of multimodal management of metastatic colorectal cancer. Methods A retrospective population‐based study was conducted on patients with metastatic colorectal cancer in Central Finland in 2000–2015. Clinical and histopathological data were retrieved and descriptive analysis was conducted to determine the pattern of metastatic disease, defined as synchronous, early metachronous (within 12 months of diagnosis of primary disease) and late metachronous (more than 12 months after diagnosis). Subgroups were compared for resection and overall survival (OS) rates. Results Of 1671 patients, 296 (17·7 per cent)…

MaleLung NeoplasmsPROGNOSISColorectal cancerGastroenterology0302 clinical medicineEpidemiologyEPIDEMIOLOGYStage (cooking)FinlandAged 80 and overeducation.field_of_studyIncidenceIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle Aged3. Good healthSurvival Ratemedicine.anatomical_structureHPB030220 oncology & carcinogenesisSURVIVALLower GIFemaleOriginal Article030211 gastroenterology & hepatologysyöpätauditMetastasectomyColorectal Neoplasmsmedicine.medical_specialtyRESECTIONesiintyvyysPopulationlcsh:Surgerycolorectal cancersuolistosyövätLIVER METASTASESetäpesäkkeet03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective StudiespaksusuolisyöpäLungbusiness.industryMetastasectomyRetrospective cohort studyOriginal Articleslcsh:RD1-8113126 Surgery anesthesiology intensive care radiologymedicine.diseasebusiness
researchProduct

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct

β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

2014

Abstract The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show that β-catenin is essential for development of EGFR-mutated lung cancers. β-Catenin was upregulated and activated in EGFR-mutated cells. Mutant EGFR preferentially bound to and tyrosine phosphorylated β-catenin, leading to an increase in β-catenin–mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Pharmacologic inhibition of β-catenin suppresse…

Cancer ResearchLung NeoplasmsCarcinogenesisAfatinibMutation MissenseAntineoplastic AgentsMice TransgenicAfatinibmedicine.disease_causeArticleTransactivationGefitinibCarcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansEpidermal growth factor receptorLung cancerbeta CateninMutationbiologyProtein Stabilitymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenUp-Regulationrespiratory tract diseasesErbB ReceptorsGene Expression Regulation NeoplasticHEK293 CellsOncologyDoxycyclineCateninImmunologyQuinazolinesCancer researchbiology.proteinCarcinogenesismedicine.drugCancer Research
researchProduct